We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Brand and generic pharmaceutical manufacturers in South Africa, as well as multinational firms, launched a new industry association Nov. 22 aimed at addressing local health needs by bringing quality medicines to the South African market.
Elite Pharmaceuticals is teaming up with VGS Pharma to create a research and development company geared toward manufacturing specialty generic drugs, the company announced.
Merck expects its drug development pipeline, including three expected new drug applications (NDAs) in 2007, to contribute to high earnings growth, the company announced.
More than 800 stores in 11 additional states are set to offer consumers 30-day supplies of generic prescription drugs for $4, due to another round of expansions to the Wal-Mart program.
Merck and Idera Pharmaceuticals announced a collaboration to incorporate Idera’s toll-like receptor (TLR) agonists into vaccines Merck is developing for oncology, infectious diseases and Alzheimer’s disease.
Economic growth and a desire to improve the overall quality of and access to healthcare services should make Latin America an enticing market for medical device manufacturers.
Pfizer’s sudden decision to end its clinical trials for torcetrapib, a once-likely successor to its blockbuster cholesterol drug Lipitor, not only harms its financial outlook, but also opens the door for other companies to take control of that market, analysts say.
Merck continues to predict growth in its earnings per share (EPS) for 2007, due to high expectations for its new products and savings from a global restructuring plan. Read More
Lawmakers should not interfere with the current off-label prescribing system because doing so would limit patients’ access to the most innovative treatments, a high-ranking FDA official says. Read More